COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE) (MUSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02637232
Recruitment Status : Completed
First Posted : December 22, 2015
Last Update Posted : May 18, 2016
Chiltern International Inc.
Information provided by (Responsible Party):

Brief Summary:
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.

Condition or disease Intervention/treatment
Rosacea Other: Mirvaso® / Onreltea TM

Layout table for study information
Study Type : Observational
Actual Enrollment : 302 participants
Time Perspective: Prospective
Official Title: Mirvaso® Utilisation and Patient Satisfaction Evaluation
Study Start Date : October 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rosacea

Group/Cohort Intervention/treatment
Mirvaso® / Onreltea TM Other: Mirvaso® / Onreltea TM

Primary Outcome Measures :
  1. Satisfaction among patients to whom Mirvaso®/OnrelteaTM is prescribed (% of subjects across score per question). [ Time Frame: Week 4 ]
    % of subjects across score per question.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patient with persistent facial erythema of rosacea

Inclusion Criteria:

  • Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM according to package insert

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02637232

Layout table for location information
Investigator site 1
Hamilton, Canada
Sponsors and Collaborators
Chiltern International Inc.
Layout table for additonal information
Responsible Party: Galderma Identifier: NCT02637232    
Other Study ID Numbers: RD.03.SPR.104160
First Posted: December 22, 2015    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs